Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06686121 · ClinicalTrials.gov registry record · Phase 3

Improving Mobility After Revascularization in Peripheral Artery Disease

A Phase 3 study of Peripheral Artery Disease and Mobility Limitation, sponsored by Northwestern University.

Recruiting
Registry status
Phase 3
Development phase
386
Enrollment target
7
Study locations

NCT06686121: Recruiting Phase 3 study of Peripheral Artery Disease and Mobility Limitation, sponsored by Northwestern University.

NCT06686121 is a Phase 3 study of Peripheral Artery Disease and Mobility Limitation that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 386 participants, above the 119-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (224% higher). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06686121, a Phase 3 study of Peripheral Artery Disease and Mobility Limitation, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
Phase 3
Development phase
386 participants
Enrollment target
7
Study locations

Study Summary

Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD. Investigators further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. In a randomized clinical trial with a 2 x 2 factorial design, the trial will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).

Primary Outcome

Distance walked in six minutes

Interventions

  • BEHAVIORAL Attention Control
  • BEHAVIORAL Home Based Exercise
  • DRUG Nitrate Rich Beetroot Juice
  • DRUG Placebo Beetroot Juice Without Nitrate

Study Locations (7)

Illinois

  • Northwestern University Feinberg School of Medicine - Chicago
  • University of Chicago - Chicago

Arizona

  • University of Arizona - Tucson

California

  • Rancho Research Institute - Downey

Georgia

  • Emory University School of Medicine - Atlanta

New Hampshire

  • Dartmouth Hitchcock Medical Center - Lebanon

Pennsylvania

  • University of Pittsburgh - Pittsburgh

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2025-08-04
Est. Completion 2032-08-01
Phase Phase 3
Northwestern University

1,209 total trials

What NCT06686121 shows while recruiting

NCT06686121 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (224% higher).

The record links to 5 conditions, with Peripheral Artery Disease appearing as the primary indexed condition, and to 4 interventions - of which Attention Control is the first listed.

NCT06686121 lists 7 locations in 6 states (Illinois, Arizona, California).

Frequently Asked Questions

What is clinical trial NCT06686121 about?

NCT06686121 is a clinical study titled "Improving Mobility After Revascularization in Peripheral Artery Disease". Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. Investigators...

What is the current status of trial NCT06686121?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 386 participants. The study started on 2025-08-04. Estimated completion is 2032-08-01.

What conditions does trial NCT06686121 study?

This clinical trial studies the following conditions: Peripheral Artery Disease, Mobility Limitation, Peripheral Vascular Disease, Intermittent Claudication, Revascularization.

What interventions are being tested in trial NCT06686121?

The interventions under investigation include: Attention Control (BEHAVIORAL), Home Based Exercise (BEHAVIORAL), Nitrate Rich Beetroot Juice (DRUG), Placebo Beetroot Juice Without Nitrate (DRUG).

Who is sponsoring clinical trial NCT06686121?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06686121 being conducted?

This trial has 7 study locations across Arizona, California, Georgia, Illinois, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06686121's enrollment target sits among peer trials

386 4th of 50 higher than 47 of 50 other Peripheral Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645107 · 386 participants · Phase 3

    A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • NCT05896189 · 386 participants · NA

    Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

  • NCT07424547 · 386 participants · Phase 1

    Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

  • NCT03761108 · 387 participants · Phase 1

    Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06686121, the US trial registry maintained by the National Library of Medicine. NCT06686121 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.